HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.

By PharmaVoice · Apr 17, 2026 · via PharmaVoice
Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
moneyformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
RA Capital banks $75M for a biotech SPAC
MoneyBioPharma Dive ↗
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
May 21, 2026
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
MoneyFierceBiotech ↗
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
May 13, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
MoneyFiercePharma ↗
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
May 12, 2026